The University of Chicago Header Logo

Connection

Bruce Brockstein to Bevacizumab

Back to Details
This is a "connection" page, showing publications Bruce Brockstein has written about Bevacizumab.
Bruce Brockstein
Connection Strength
0.025
Bevacizumab
  1. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan; 24(1):257-63.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.